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         In drug delivery, microneedles offer many unique characteristics which can 
improve the delivery of drugs into delicate tissues and tissue systems.  These needles can 
be fabricated from a variety of materials including metals, ceramics, and polymers.  This 
project aims to demonstrate a carbon nanotube based microneedle is also possible.  By 
growing vertically aligned carbon nanotubes around a pore, these new microneedles can 
significantly decrease the diameter of needles used for drug delivery into delicate tissue.  
Needle diameter is an important factor for drug delivery into delicate tissues such as the 
central nervous system due to the body’s natural healing reponse, glial scarring.  By 
significantly decreasing the needle size from millimeters to nanometers, the amount and 
size of glial scarring can be reduced and therefore improve drug delivery.  Although no 
complete samples were successfully fabricated in this study, much knowledge and insight 






INTRODUCTION AND LITERATURE REVIEW 
In the medical field, new and more efficient methods of treatment are in high 
demand.  A recent boom in the nanotechnology field has opened a limitless field for 
expansion and development.  Carbon nanotubes (CNTs), in particular, offer unique 
properties that could revolutionize certain medical procedures.  In the area of drug 
delivery, large needles are currently used to inject solutions into the body.  Certain 
aspects of current hypodermic injections, such as post-injection scarring and poor bolus 
injection absorption, are effective and have been used and accepted in the medical field 
for decades.  Currently, the smallest needles commercially available have a 300 μm outer 
diameter.
1
  The idea of using a syringe with a 20-100 μm diameter could help 
significantly improve drug delivery effectiveness and reduce discomfort.  One of the 
main areas which could be affected by this would be drug delivery into the central 
nervous system and other delicate tissues (i.e, the eye or brain).  In these areas, current 
methods of drug delivery leave glial scars which pose a problem in tissue and central 
nervous system regeneration. 
This project will aim to fabricate needle-quality CNT arrays.  Microneedles have 
been fabricated from other various materials but a CNT based microneedle has not yet 
been designed.  Through multiple trials, a detailed process will be designed for successful 
fabrication of CNT microneedles.  The focus of this project is to demonstrate that these 
CNT needles can be successfully fabricated. 
Carbon Nanotubes 
Carbon nanotubes (CNTs) in general are allotropes of carbon.
2
  There are two 
types of CNTs: single-walled CNTs (SWCNTs) and multi-walled CNTs (MWCNTs) 
(Figure 1).  They are grown as graphene sheets in a hollow cylinder shape, with 
diameters as small as 0.2 nm and lengths as long as 4 cm.
3
  CNTs have been found to 
exhibit length-to-diameter ratios up to 28,000,000:1, a ratio higher than any other 
material.  SWCNTs are composed of one cylinder, while MWCNTs contain multiple 
cylinders grown around each other.  Mechanically, CNTs have been found to be one of 
the strongest known materials due to their binding properties and interactions with 
surrounding CNTs.
4
  With an axial Young’s modulus of 1 TPa, CNTs have been found to 
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be one of the stiffest materials known.  Combined with their capacity to elastically 
deform under compression,
5
 CNTs possess the potential to successfully penetrate tissue 
surfaces.  These properties help assert the notion that the proposed nanosyringes will be 
able to tolerate forces associated with insertion, intact removal, and normal human 
movements.   
  When grown as MWCNTs, an array of nanotubes align themselves into “ropes” 
that are held together by Van der Waals forces (Figure 2).  SWCNTs and MWCNTs 
exhibit high electrical and thermal conductivity, along with excellent chemical and 
thermal stability.
2
  Certain properties of CNTs are determined by their crystallographic 
orientations described as: armchair, zigzag, and chiral.  In terms of electrical 
conductivity, armchair CNTs are known to be metallic and therefore good conductors.  In 
zigzag or chiral structures, they are found to be moderate to strong semiconductors with 
varying band gap lengths. 
 
                               
Figure 1: Single-walled vs. Multi-walled CNTs
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A potential advantage of using the proposed nanosyringe in drug delivery is the 
capability of avoiding glial scarring.  Glial scarring is a natural response from the central 
nervous system to repair damaged tissue.  Due to the low regenerative capacity of the 
central nervous system, a drug delivery system which could prevent glial scarring is 
desired.
11
  This response serves well in immediately protecting the damaged tissue, but 
ultimately inhibits axonal regeneration and remyelination.
12
  Taking advantage of a 
nanometer-diameter nanosyringe, a complete lack of gliotic response can be achieved.  
3 
 
With no gliotic response, there would be no damage to the central nervous system or 
surrounding tissue. 
It is unlikely than an entire lack of gliotic response will be seen.  However, by 
decreasing the diameter of tissue penetration, the size of the response could be 
minimized.  Current needles used for drug delivery range in diameter from 3.404 mm to 
0.203 mm.
13
  Therefore, using CNTs to create a syringe on the μm-level, the diameter of 
the needle will be decreased by many magnitudes.   
 
Figure 3: Scanning electron image of a 500 μm tall microneedle next to a 27 gauge hypodermic needle with 
a diameter of 3.4 mm (Davis et al).  
 
Additionally, by treating the injured area post-injection, the central nervous 
system may be able to successfully regenerate and heal itself.  The gliotic response 
occurs by recruiting reactive astrocytes to the site of the wound.  These astrocytes help to 
successfully protect and seal the wound as an immediate response, but ultimately inhibit 
CNS regeneration.  Upon arrival at the damaged site, astrocytes release chondroitin and 
keratan sulphate proteoglycans (types of proteins).  These specific proteoglycans have 
been found to inhibit axonal regeneration and remyelination.
15, 16
  Therefore, by 
combining chondroitin and keratin sulphate inhibitors with the drug to be delivered, CNS 
regeneration could potentially be avoided.  However, further research will need to be 
performed to ensure that inhibition of these proteoglycans will not have adverse effects 
on other physiological responses.  Injection into the CNS will affect the area of injection, 
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but will also be absorbed into the blood stream and distributed through the body.  Any 
effect downstream from the site of injection could have hazardous effects on the patient, 
so additional effects of these inhibitors must be analyzed before use.     
Current use of Microneedles 
The idea of a micro-sized needle has already been researched extensively.  These 
microneedles have been fabricated from silicon, metals, and polymers.  There are unique 
advantages to microneedles compared to currently used needles.  An advantage of using 
these microneedles is that with a smaller needle comes less compression on the tissue as 
the needle is inserted.  This decreased compression can lead to less compression on pain 
receptors as well as discomfort associated with the insertion of a large diameter needle.
1
  
One concern with microneedles is the force needed to break the tissue barrier.  By 
definition, stress is inversely proportional to the area over which a force is applied.  
Therefore, as the radii of the needle decreases, less force is required to insert the needle.
1
  
One study, similar to the proposed nanosyringe, used 200 μm long silicon needles with 
diameters of 40μm.
17
  Using these parameters, they were able to successfully break the 
epidermal skin barrier and inject the desired fluid.  In looking at this application, another 
study showed that fluid flow through MWCNTs with diameters of 7 nm was possible 
with about 1 atm applied pressure.
18
  
Although fluid flow through single walled CNTs (SWCNTs) and multi walled 
CNTs (MWCNTs) has been demonstrated,
18
 flow through vertically aligned CNTs 
(VACNTs) is still unclear.  By combining different sized and shaped CNT arrays with 
different sized and shaped delivery pores, it is possible to show that fluid flow through 
VACNTs is possible and efficient.   
Lessons Learned 
 It has been shown that CNTs possess mechanical properties which should allow 
them to successfully penetrate tissue barriers.  Additionally, since fluid flow has been 
demonstrated through individual CNTs, the idea of demonstrating fluid flow through 
VACNTs seems probable.  Since these VACNTs will be grown at diameters larger than 
those of individual CNTs, fluid should be able to flow through at applicable rates.  
Microneedles have already been tested for use as drug delivery systems into delicate 
tissue to avoid glial scarring.  By creating these microneedles out of CNTs, smaller 
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needle diameters can be achieved and glial scarring can be avoided even more.  Finally, 
although the biocompatibility of CNTs is still unclear, further testing can be performed to 
better understand this concept.  If a CNT based needle could be used and extracted from 
the tissue without breaking off inside the tissue, then the asbestos-like shape of CNTs 
would have no adverse affect on the body.  Furthermore, through proper purification 
techniques during CNT fabrication, harmful metals and toxic chemical residues can be 
removed from the CNT-based microneedles.  
 The goal of this project is to demonstrate that CNT-based microneedles can be 
successfully fabricated.  To properly function as desired, these microneedles must 
possess the mechanical strength of raw CNTs while also maintaining their small 
micrometer diameters.  Furthermore, these CNT microneedles must be able to deliver 
fluid through the CNT to efficiently meet drug delivery purposes.  Multiple steps are 
necessary to fabricate the desired CNT-based microneedle.  The two primary steps for 
this process are pore generation through a silicon wafer, followed by VACNT growth 






VACNTs were grown on a silicon wafer around a through via in the wafer 
(Figures 4 and 5).  Shapes to be grown and tested included squares, stars, diamonds, 
triangles, and circles ranging in size from 20 μm to 100μm in width.  In total, a maximum 
of 21 different sample combinations of pore and array variations could be tested from a 
fully completed wafer.  Each sample contained a 10x10 array of homogeneous 
combinations.  These different combinations were achieved using a specifically designed 
pattern.  The photolithographic mask (referred to as Holey-Wafer Mask (HWM), seen in 
Figure 13) was used to create both the pores and VACNT arrays.  The first step, creating 
the pores through the wafer, was accomplished using the mask in its normal orientation.  
Once pores were created, the mask was able to be rotated either 90° clockwise (CW), 
90°counter-clockwise (CCW), or 180° CW / CCW.  This allowed for different shape and 
size combinations to be achieved.   
Pores were etched through the silicon wafer using a Surface Technology Systems 
Inductively Coupled Plasma (STS ICP) tool.  Once pores were been created, the same 
design pattern used for pores will be developed on the wafer but in a rotated position to 
overlap different shapes and sizes.  Using chemical vapor deposition (CVD) equipment, 
VACNTs will be grown on the new pattern. 
A detailed table showing all possible combinations upon rotation is shown in 
Figure 16.  It should be noted that a 90° CW rotation yields 21 usable combinations, and 
will therefore yield the most usable combinations.  Therefore, the masked was to be 
rotated in this direction to generate the most samples.                              
Actual steps to create the final product are shown in detail in Figures 14 and 15 in 
the appendix.  Figure 14 details the steps and tools necessary to create the pores in the 
wafer, while Figure 15 explains the process required to create the VACNT arrays on top 






































Figure 4: A scanning electron image of 
VACNTs grown around a circular pore.  
This image shows the inner ring of the 
VACNT array. 
Figure 5: A CAD image of a proposed 
nanosyringe demonstrates a cross sectional view 
of the expected results.  A tower of VACNTs is 





        Although no complete sample was fabricated during this project, the total process 
for creating the samples was critiqued and improved.  Multiple attempts were made to 
create a functional sample but failed at some step in the process.  The causes for these 
failures were documented and taken into account for the following trials.  The majority of 
this project looked at finalizing the process steps necessary to complete the first phase of 
the experiment, pore generation.   
        Initially, samples were fabricated on a 3 inch Silicon wafer.  In total, five samples 
were created and developed up to the point of etching.  Photoresist application and 
development parameters and exposure settings were all varied to determine the best 
setting.  Parameter specifics for these samples can be found in the appendix in Figure 17.    
After the samples had been created, one sample was chosen to be etched.  The 3 inch 
wafer to be etched was mounted onto a 4 inch carrier wafer to protect the machine during 
the etching process.  The wafer was mounted using and placed on top of the carrier wafer, 
photoresist side up.  An error occurred inside the STS ICP during the etching process.  
Since the 3 inch sample wafer did not fully cover the 4 inch carrier wafer, this left the 
outer silicon portion of the carrier wafer exposed to the plasma etching.  Therefore, the 
ICP etched away at the sample wafer as well as the carrier wafer edge, causing the carrier 
wafer to break and shatter during processing.  The sample was lost and actions were 
taken to fix this problem.  
        Following the failure of the 3 inch wafers, it was noted that 4 inch wafers had to be 
used in order to utilize the STS ICP.  Due to the larger wafer size, photoresist parameters 
were altered to ensure good results.  These parameters can be found in the appendix in 
Figure 18.  After etching in the ICP, the sample was visually analyzed to determine 
results from the etch process.  It could be seen that all pores were not etched completely 
through the wafer.  A cross-sectional analysis was performed to determine the clarity of 
the pores (Figure 7).  This analysis revealed that the pores were being accurately etched 
with clean side-wall profiles, but not completely through the wafer.  Images of the top 
and back side of the wafer, seen in Figure 6, show that the etch was not complete.  
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Additionally, visual analysis of the shape clarity showed that the clarity of the shapes was 
not as definitive as desired (Figures 8 and 9).  These results indicated that a longer etch 
time and alterations to pattern development were necessary.   
 
 
Figure 6: SEM images of top and back side of etched wafer.  These images show a 100 μm wide square 
array.  As seen in 6A, the all pores on top are etched.  However, in 6B, it can be seen that all pores are not 
fully etched, with some not even breaking the back side of the wafer. 
 
 
Figure 7: Cross-sectional view of a square pore.  It can be seen that the pore has clean side walls and good 
clarity at the top.  However, the etch did not successfully penetrate through the entire wafer. 
A – Top View 




Figure 8: SEM image of a 60 μm wide star.  It can be noted that there is poor clarity in the feature 
definitions with rounded corners and a barely visible star shape.   
 
 
Figure 9: SEM image of a 100 μm wide triangle.  It can be seen that the clarity of the larger shapes is better 




        In addition to conducting trials on etching, one trial was performed to analyze 
potential CNT growth.  This trial was performed without pores through the wafers.  It 
was conducted to ensure the pattern generated on the samples would yield viable 
VACNT arrays.  Out of all possible shapes and sizes, the 20 μm square and 60 μm star 
arrays were grown and visually analyzed.  Both samples yielded mixed results, with some 
shapes growing with good clarity and others with poor shape definition.  Therefore, not 
all shapes were successfully grown.  Figures 10 and 11 present samples of successful and 
failed growth patterns for the 20 μm square array and 60 μm star array.  The vertical 
alignment of the CNTs was also analyzed and determined to be successful from the 
growth parameters (Figure 12).   
 
 
Figure 10: Images of a good and bad 20 μm square sample.   
 
 
Figure 11: Images of a good and bad 60 μm star sample. 
A – Good B - Bad 





















Figure 12: SEM image of the side view of a 60 μm star.  It can be seen that there is a clear vertical 







        Although no complete samples were successfully fabricated, valuable information 
was gained in regards to the process steps.  It was quickly realized that the initially 
proposed parameters did not perform as desired and needed to be altered.  The main areas 
of improvement came in the areas of photolithography development and through-wafer 
etching. 
Photolithography 
        After processing multiple samples through the photolithography stages, a better 
understanding of appropriate parameter settings was determined.  Processing the initial 
samples yielded acceptable results with photoresist deposition and development.  Spin 
times and settings for photoresist application can still be improved and should be 
investigated further.  Initially, spin time and ramp speed for photoresist application were 
started low and slowly increased until an optimal photoresist spread was achieved.  It was 
determined that a spin speed of 3000 rpm, with a ramp of 1500 rpm/sec for 40 seconds 
yielded appropriate results.  Additionally, a clear decision was never made as to the best 
type of contact mode during exposure between the wafer and mask.  A hard contact was 
used for these samples, but other types of contact should be analyzed.  Furthermore, 
development time after exposure was never fully determined.  Many different 
development times were tested and yielded positive results.  It was determined that the 
wafer should be developed for 60 seconds initially and then microscopically verified.  
From here, the wafer should be developed for an additional 15 seconds and verified after 
each development.  Development times varied by a small bit between all samples, 
demonstrating that development should be performed and microscopically verified before 
any further steps are taken. 
Wafer Etching 
        Although only two samples were able to etched, each sample provided valuable 
information for future samples.  The first three inch wafer sample shattered in the ICP 
due to an error with the carrier wafer.  It was noted that the exposed silicon on the carrier 
wafer was etched along with the sample pores, causing the carrier wafer to shatter and 
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break.  This mistake was easily fixed and new samples were fabricated with the four inch 
wafers.  Although the second sample was not fully etched through, it still provided 
valuable information about the processing.  The wafer was diced and visually analyzed to 
determine the clarity and quality of the results.  Cross-sectional analysis showed that the 
pores were being etched properly and that the etch time had to be increased in order to 
etch through the wafer.  This cross-sectional analysis also demonstrated that an etch 
phase of 8 seconds followed by a 10 second passivation phase was sufficient.  When 
determining etch time, the main difficulty arose from the varying shapes and sizes.  Not 
all shapes would etch at the same rate or manner.  It was known that the larger shapes 
would etch faster than their smaller counterparts.  Additionally, a simple shape such as a 
circle or square would etch faster than a star due to the complex turns and curves of a 
star.  Etch times were started at 3 hours for fear of damaging the machine.  This sample 
yielded insufficient etching and the etch time was increased for the next trial.  Therefore, 
further studies need to be performed to determine an optimal etching time.  From these 
results, it is believed than an etch time of four hours should be an effective etch time.  
This optimal time will allow enough time to successfully etch through all smaller and 
more difficult shapes while still maintaining clarity in the larger ones.  It was feared that 
some shapes may be overexposed to the etching and lose their clarity.   
Future Studies 
        Results from these experiments provided insight into potential uses of VACNT 
arrays.  Future studies should be performed to determine more accurate and precise 
processing parameters to yield successful results for all trials.  Once a successful VACNT 
array has been grown around pores, these samples can be tested for potential uses.  A 
potential use for these arrays would be for drug delivery into delicate tissues.  In order to 
determine this, a fluid flow analysis would need to be performed to ensure that drug 
delivery is possible.  Additionally, the VACNT arrays can be functionalized to attach 
specific biochemicals and drugs to them for treatment.  Finally, for future use with drug 
delivery, further testing must be performed on CNT biocompatibility and tissue 






        This project aimed at developing a process to create a drug eluting nanoelectrode 
array.  Results from this experiment have indicated that a functional VACNT array is 
possible to create.  Trials were performed to better understand the optimal processing 
parameters required to etch through the wafer and to then grow VACNTs around the 
pores.  All experimental results have been analyzed and taken into account for future 
trials.  It was demonstrated that clear etching results are possible and can be obtained by 
increasing the etching time.  Additionally, results showed that the CNTs can be grown in 
the desired shapes with acceptable clarity.  Therefore, future studies will look at 








Figure 13: Holey-Wafer Mask.  As mentioned previously, 32 different shape and size combinations exist, 













Process Equipment Description / Equipment Specifics 




Karl Suss RC8 
Spinner 
Using Futurrex NR5-8000 Negative PR, 
apply ~10 μm thick layer. 
Soft Bake PR Hot Plate / Oven Temperature and time variant. 
Exposure Karl Suss MA-6 
Mask Aligner 
Hard contact at 365 nm.
 
Develop Lab Glassware Develop using Futurrex RD6 Developer 
Hard Bake PR Hot Plate / Oven Temperature and time variant. 
Mount on Carrier 
Wafer 
Hot Plate & Cool 
Grease 
Heat carrier wafer on 65°C Hot Plate, 
apply cool grease and mount test wafer 
on top. 
Etch Pores STS ICP Optimal time and parameters to be 
determined. 
Strip and Clean 
Wafer 
PR Stripper & CMOS 
Station 
Acetone, Futurrex RR4 PR Stripper, DI 
Rinse, CMOS Cleaning Station. 
Verify Results Scanning Electron 
Microscope (SEM) 
Hitachi S-800 SEM to verify clarity of 
pores. 
Figure 14:  Detailed steps required to create pores through test wafer. 
 
VACNT Array Growth 
Process Equipment Description / Equipment Specifics 
PR Application CEE 100CB Spinner, 
Futurrex NR5-8000 
Futurrex NR5-8000 PR thickness less 
than before, thickness TBD.   
Soft Bake PR Hot Plate / Oven TBD based on thickness. 
Exposure Karl Suss MA-6 Mask 
Aligner 
Hard contact at 365 nm.
 
Develop Lab Glassware, Futurrex 
RD6 Developer 
Exposure time by PR thickness. 
Hard Bake PR Hot Plate / Oven TBD by PR thickness. 
Iron Deposit Thermal Evaporator  0.01 grams of 99.999% pure Fe wrapped 
around tungsten filament. 
Strip and Clean 
Wafer 
PR Stripper & CMOS 
Station 
Acetone, Futurrex RR4 PR Stripper, DI 
Rinse, CMOS Piranha bath. 
Grow CNTs PECVD or CVD Recipe TBD 
Verify Results Scanning Electron 
Microscope (SEM) 
Hitachi S-800 SEM to verify successful 
VACNT array growth 







90° CCW 90° CW 180° CW / CCW 
Hole Outside Hole Outside Hole Outside 
1 20 ring 100 ring 20 ring 60 ring 20 ring 80 ring 
2 20 diamond 100 
diamond 
20 diamond 60 diamond 20 diamond 
80 diamond 
3 20 square 60 square 20 square 60 square 20 square 80 square 
4 20 star 100 star 20 star 60 star 20 star 80 star 
5 60 star 20 star 60 star 80 star 60 star 100 star 
6 20 square 100 square 20 square 60 square 20 square 80 square 
7 20 triangle 100 triangle 20 triangle 60 triangle 20 triangle 80 triangle 
8 20 circle 100 circle 20 circle 100 circle 20 circle 80 circle 
9 100 square 80 square 100 square 20 square 100 square 60 square 
10 100 ring 80 ring 100 ring 20 ring 100 ring 60 ring 
11 60 square 20 square 60 square 80 square 60 square 60 square 
12 60 circle 20 circle 60 circle 80 circle 60 circle 100 circle 
13 20 star 100 star 20 star 60 star 20 star 80 star 
14 100 star 80 star 100 star 20 star 100 star 60 star 
15 100 triangle 80 triangle 100 triangle 20 triangle 100 triangle 60 triangle 
16 100 
diamond 
80 diamond 100 
diamond 
20 diamond 100 
diamond 60 diamond 
17 60 diamond 20 diamond 60 diamond 80 diamond 60 diamond 100 
diamond 
18 60 triangle 20 triangle 60 triangle 80 triangle 60 triangle 100 triangle 
19 60 star 20 star 60 star 80 star 60 star 100 star 
20 80 star 60 star 80 star 100 star 80 star 20 star 
21 100 circle 80 circle 100 circle 20 circle 100 circle 60 circle 
22 60 square 80 square 60 square 20 square 60 square 60 square 
23 60 ring 20 ring 60 ring 80 ring 60 ring 100 ring 
24 60 square 20 square 60 square 20 square 60 square 100 square 
25 80 circle 60 circle 80 circle 100 circle 80 circle 20 circle 
26 80 triangle 60 triangle 80 triangle 100 triangle 80 triangle 20 triangle 
27 80 square 60 square 80 square 100 square 80 square 20 square 
28 100 star 80 star 100 star 20 star 100 star 60 star 
29 80 star 60 star 80 star 100 star 80 star 20 star 
30 80 square 60 square 80 square 60 square 80 square 20 square 
31 80 diamond 60 diamond 80 diamond 60 diamond 80 diamond 20 diamond 
32 80 ring 60 ring 80 ring 100 ring 80 ring 20 ring 






Key Color Description 
   Usable combination at 90° CCW 
 Usable combination at 90° CW 
 Usable combination at 180° 
 Unusable combination 
Figure 16: Table showing possible combinations of pore and array upon different rotations. 
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Parameter Value / Setting 
PR Spinner Speed = 2000 rpm, Ramp = 1000 rpm/sec, 
Time = 40 secs. 
Soft Bake 4 mins @ 150 °C 
Expose Contact = Hard Contact, Time = 44 secs @ 
365 nm, I = 5.6 mW/cm
2
. 
Hard Bake 3.5 mins @ 100 °C 
Develop 105 secs 
Etch Etch = 10 secs, Pass = 8 secs, 750 cycles 
Figure 17: Trial 1 parameters for samples created using 3 inch wafers.  This sample broke during the 
etching process. 
 
Parameter Value / Setting 
PR Spinner Speed = 3000 rpm, Ramp = 1500 rpm/sec, 
Time = 40 secs. 
Soft Bake 3.5 mins @ 150 °C 
Expose Contact = Hard Contact, Time = 31 secs @ 
365 nm, I = 6.0 mW/cm
2
. 
Hard Bake 3.5 mins @ 100 °C 
Develop 90 secs 
Etch Etch = 10 secs, Pass = 8 secs, 750 cycles 
Figure 18: Trial 2 parameters using 4 inch wafers.  This sample did not etch completely through the wafer 
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